Embed Size (px)
Citation preview
Avgo Biotech
[email protected] www.rec-egg.com Avgo Biotech
Making money from industrial food waste
Toxic Heavy Metals in Calcium Carbonate cost European Pharma Industry
> €40 M
• 250k Tonnes of eggshell waste, cost European industry >€85m.
• “Rec-Egg” engine – Converts Waste eggshells into low heavy metal Calcium Carbonate (CaCO3).
[email protected] www.rec-egg.com Avgo Biotech
• We can produce 300kg of CaCO3 /day
• Require funding to develop a demonstrator • Capable of working at 1 Tonne / day
• Validate the scale in front of the egg processors • This would enable implementation in their factories
[email protected] www.rec-egg.com Avgo Biotech
Road to the “Rec-Egg” engine
Funding to date
• Grants - IUK, BBSRC and RDF – totaling £443k. • Loans – EFG and RDF (repaid) – totaling £ 97.5k.
• Personal funds.
Achievements • The “Rec-Egg” engine produces:
• ZERO WASTE. • Low Heavy Metal CaCO3.
• Recovers Egg Shell Membrane and Processing Aids. • Produces other valuable products for wound care
[email protected] www.rec-egg.com Avgo Biotech
Input Costs - €4000 / Tonne
Output Revenues €14,000k / Tonne
Multi Products - Zero Waste
Egg Shells
The Value Proposition
Food Industry
Cost €85 Million
GP
€10,000 / Tonne
Pharmaceutical Industry Cost €40 Million
[email protected] www.rec-egg.com Avgo Biotech
The Calcium Carbonate Market
100k T
300k T Medical
14m T Global
European Medical
100k T, €200 million
10% penetration 10k T, €20 million
[email protected] www.rec-egg.com Avgo Biotech
Approx. 10% of UK market
Brunel & Protec Nutra
1k T pa
European Market 100k T pa
UK Market 10k T pa
Bottom up
Top Down
European Market is 10x UK
Revenue Model - Licensing
Calcium Carbonate
Pharmaceutical Company
Egg Processing Company
Manufacturing / Chemical Company
–
Licensing deal with a company offering:
Expertise in Manufacturing
Familiarity with Supply Chains
Medical and Pharmaceutical facing
-
Takes raw eggshells at zero cost
- Raw eggshell is processed
€0-€100/t
Benefit Approx.
£100/tonne
€2,000/t
Medical device Company €2,000/t
Plastics Company
Formulation Companies
[email protected] www.rec-egg.com Avgo Biotech
Avgo’s value comes from licensing fees, based on upfront, milestone and revenues
Revenue models for wound care and synthetic biology not
considered here
Competition - positioning
[email protected] www.rec-egg.com Avgo Biotech
The “RECEGG” process generates the best product on the market, offering a unique combination of:
• Outstanding purity, and • Sustainable and Environmental credentials
Other products are unable to offer this!
AvgoEgg S
hell
Natura
l
Precip
itate
d
Price H M VH M
Purity H L M H
Sustainability H M L L
Environmental H M L L
Revenues and Profits - from processing EggShells
Licensing deal
Licensing – consisting of upfront, milestone fees, % of sales revenues - 5% (revenue €198m, income €9.8m in year 5)
Year 5 Total - Revenues €198 m Total - GP €171 m
€ ,000’s 1 2 3 4 5
Calcium Carbonate Revenue 0 113 1,050 5,250 23,750
76% GP 0 88 750 3,750 18,125
Membranes Revenue 0 0 606 3020 60,400
99% GP 0 0 600 3,019 60,387
Synthetic Biology Revenue 0 9 770 11,025 113,750
80% GP 0 -27 626 8,865 92,150
-20000
0
20000
40000
60000
80000
100000
120000
1 2 3 4 5 6
Revenues and Gross Profit
Calcium Carbonate Calcium Carbonate Membranes
Calcium Carbonate Synthetic Biology Calcium Carbonate
Year 5 CaCO3 - Revenues €24 m CaCO3 - GP €18 m
The Team
Andrew Stacey – founder and business lead. 25 years in Sales and Marketing in the Research Markets with global companies. Working with start up businesses for the past 10 years.
Professor Carole Perry’s leads a technical Biomaterials team at Nottingham Trent University, research supported by UK / US Gov. and US / European
companies.
Dr. Sarah Gaunt – Project Management / Intellectual Property / Licensing – 2 products in multi-million £ global licensing deals, with Tate and Lyle
[email protected] www.rec-egg.com Avgo Biotech
Barbara Demetriou - Accountant – works with many start up companies – raising grant, loan and equity finance. Providing Financial Control
We require €1.2m, to:
• Rapidly scale up a demonstrator – 1 Tonne/day, meeting proof requirements of the Egg processors.
• Over 18-24 months.
• Providing - Early product.
• Develop - supply chain / market - UK and Europe.
Avgo Biotech is SEIS registered.
In Summary
[email protected] www.rec-egg.com Avgo Biotech
Andrew Stacey
07802 888742 [email protected]
www.rec-egg.com
STAND 20
Up to €125 Million
Waste
Up to €1,000 Million Gross Profit
Avgo Biotech
